相似文献
1
Baseline susceptibility of primary human immunodeficiency virus type 1 to entry inhibitors.
J Virol. 2003 Jan;77(2):1610-3. doi: 10.1128/jvi.77.2.1610-1613.2003.
2
Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120.
J Virol. 2000 Sep;74(18):8358-67. doi: 10.1128/jvi.74.18.8358-8367.2000.
3
Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.
Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16249-54. doi: 10.1073/pnas.252469399. Epub 2002 Nov 20.
4
Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor.
J Virol. 2001 Sep;75(18):8605-14. doi: 10.1128/jvi.75.18.8605-8614.2001.
5
Biological and genetic characterization of a human immunodeficiency virus strain resistant to CXCR4 antagonist T134.
AIDS Res Hum Retroviruses. 2001 May 1;17(7):615-22. doi: 10.1089/088922201300119716.
6
Variable sensitivity of CCR5-tropic human immunodeficiency virus type 1 isolates to inhibition by RANTES analogs.
J Virol. 2000 May;74(10):4868-76. doi: 10.1128/jvi.74.10.4868-4876.2000.
7
Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).
Virology. 2005 Jul 20;338(1):182-99. doi: 10.1016/j.virol.2005.04.035.
8
The bis-azo compound FP-21399 inhibits HIV-1 replication by preventing viral entry.
Virology. 1998 May 10;244(2):530-41. doi: 10.1006/viro.1998.9115.
9
AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor.
Nat Med. 1998 Jan;4(1):72-7. doi: 10.1038/nm0198-072.
10
HIV-1 entry and its inhibition.
Curr Top Microbiol Immunol. 2003;281:1-27. doi: 10.1007/978-3-642-19012-4_1.
引用本文的文献
1
The Phenomenon of Antiretroviral Drug Resistance in the Context of Human Immunodeficiency Virus Treatment: Dynamic and Ever Evolving Subject Matter.
Biomedicines. 2024 Apr 20;12(4):915. doi: 10.3390/biomedicines12040915.
2
Pace of Coreceptor Tropism Switch in HIV-1-Infected Individuals after Recent Infection.
J Virol. 2017 Sep 12;91(19). doi: 10.1128/JVI.00793-17. Print 2017 Oct 1.
3
Multifaceted mechanisms of HIV inhibition and resistance to CCR5 inhibitors PSC-RANTES and Maraviroc.
Antimicrob Agents Chemother. 2013 Jun;57(6):2640-50. doi: 10.1128/AAC.02511-12. Epub 2013 Mar 25.
4
Mechanism of resistance to S138A substituted enfuvirtide and its application to peptide design.
Int J Biochem Cell Biol. 2013 Apr;45(4):908-15. doi: 10.1016/j.biocel.2013.01.015. Epub 2013 Jan 26.
5
Escape from human immunodeficiency virus type 1 (HIV-1) entry inhibitors.
Viruses. 2012 Dec;4(12):3859-911. doi: 10.3390/v4123859.
6
HIV-1 resistance to maraviroc conferred by a CD4 binding site mutation in the envelope glycoprotein gp120.
J Virol. 2013 Jan;87(2):923-34. doi: 10.1128/JVI.01863-12. Epub 2012 Nov 7.
7
HIV-1 antiretroviral drug therapy.
Cold Spring Harb Perspect Med. 2012 Apr;2(4):a007161. doi: 10.1101/cshperspect.a007161.
8
HIV-1 Entry, Inhibitors, and Resistance.
Viruses. 2010 May;2(5):1069-1105. doi: 10.3390/v2051069. Epub 2010 Apr 29.
9
Impact of the HIV-1 env genetic context outside HR1-HR2 on resistance to the fusion inhibitor enfuvirtide and viral infectivity in clinical isolates.
PLoS One. 2011;6(7):e21535. doi: 10.1371/journal.pone.0021535. Epub 2011 Jul 8.
10
Baseline genotypic and phenotypic susceptibilities of HIV-1 group O to enfuvirtide.
Antimicrob Agents Chemother. 2010 Sep;54(9):4016-9. doi: 10.1128/AAC.00100-10. Epub 2010 Jun 14.
本文引用的文献
1
Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.
Antimicrob Agents Chemother. 2002 Jun;46(6):1896-905. doi: 10.1128/AAC.46.6.1896-1905.2002.
2
Researchers explore new anti-HIV agents.
JAMA. 2002 Apr 3;287(13):1635-7. doi: 10.1001/jama.287.13.1635.
3
HIV-1 entry and how to block it.
AIDS. 2001;15 Suppl 5:S3-11. doi: 10.1097/00002030-200100005-00002.
4
World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing.
AIDS. 2001 Sep 7;15(13):1671-7. doi: 10.1097/00002030-200109070-00010.
5
Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor.
J Virol. 2001 Sep;75(18):8605-14. doi: 10.1128/jvi.75.18.8605-8614.2001.
6
Chemokine receptors as anti-retroviral targets.
Curr Drug Targets. 2001 Mar;2(1):21-39. doi: 10.2174/1389450013348849.
7
Primary genotypic resistance of HIV-1 to the fusion inhibitor T-20 in long-term infected patients.
AIDS. 2001 May 4;15(7):935-6. doi: 10.1097/00002030-200105040-00015.
8
gp120: Biologic aspects of structural features.
Annu Rev Immunol. 2001;19:253-74. doi: 10.1146/annurev.immunol.19.1.253.
9
Determination of coreceptor usage of human immunodeficiency virus type 1 from patient plasma samples by using a recombinant phenotypic assay.
J Virol. 2001 Jan;75(1):251-9. doi: 10.1128/JVI.75.1.251-259.2001.
10
Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120.
J Virol. 2000 Sep;74(18):8358-67. doi: 10.1128/jvi.74.18.8358-8367.2000.
Zotero 插件